The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 09, 2006
Filed:
May. 02, 1995
Steven H. Nye, Mequon, WI (US);
Michael J. Lenardo, Potomac, MD (US);
Henry F. Mcfarland, Gaithersburg, MD (US);
Louis A. Matis, Southport, CT (US);
Eileen Elliott Mueller, East Haven, CT (US);
John P. Mueller, East Haven, CT (US);
Clara M. Pelfrey, Gaithersburg, MD (US);
Stephen P. Squinto, Bethany, CT (US);
James A. Wilkins, Woodbridge, CT (US);
Steven H. Nye, Mequon, WI (US);
Michael J. Lenardo, Potomac, MD (US);
Henry F. McFarland, Gaithersburg, MD (US);
Louis A. Matis, Southport, CT (US);
Eileen Elliott Mueller, East Haven, CT (US);
John P. Mueller, East Haven, CT (US);
Clara M. Pelfrey, Gaithersburg, MD (US);
Stephen P. Squinto, Bethany, CT (US);
James A. Wilkins, Woodbridge, CT (US);
The United States of America as represented by the Department of Health and Human Services, Washington, DC (US);
Alexion Pharmaceuticals, Inc., Cheshire, CT (US);
Abstract
Compositions and methods are provided for the clinical assessment, diagnosis, and treatment of multiple sclerosis. The compositions of the invention are molecules related to the 21.5 kDa fetal isoform of human myelin basic protein, and include nucleic acids and polypeptides. The nucleic acid molecules of the invention are useful in the efficient production of modified and unmodified 21.5 kDa myelin basic protein polypeptides, such polypeptides being useful for assaying T cells for responsiveness to myelin basic protein epitopes. The polypeptides of the invention are also useful as therapeutic agents that act by inducing T cell responses, including apoptosis, as a means of treating multiple sclerosis.